Anthony H Goldstone
Affiliation: University College London
- Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionBella Patel
Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
Haematologica 94:1399-406. 2009..Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known...
- In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/Anthony H Goldstone
North London Cancer Network, University College London Hospitals, London, United Kingdom
Blood 111:1827-33. 2008..There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514...
- Transplantations in adult acute lymphoblastic leukemia--grounds for optimism?Anthony H Goldstone
Department of Haematology, University College London Hospitals, London NW1 2BU, United Kingdom
Clin Lymphoma Myeloma 9:S211-3. 2009..The youngest adults might not need to undergo transplantation at all. If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly...
- Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs
Department of Haematology, Royal Free and University College, London, UK
Br J Haematol 139:70-80. 2007....
- High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphomaAdrian J C Bloor
Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
Biol Blood Marrow Transplant 14:50-8. 2008..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
- Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensKirit M Ardeshna
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 130:363-72. 2005..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
- Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs
Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
Blood 103:1548-56. 2004....
- Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumabIrit Avivi
Department of Haematology, University College Hospital, London, UK
Biol Blood Marrow Transplant 10:186-94. 2004....
- Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs
Department of Haematology, University College London Hospitals, London, United Kingdom
Biol Blood Marrow Transplant 9:257-65. 2003..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti
Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
Blood 99:4357-63. 2002..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
- Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationStephen P Robinson
Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, London, United Kingdom
Blood 100:4310-6. 2002..A longer period of follow-up is required to determine the benefit of DLI and the graft-versus-lymphoma effect...
- Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphomaJonathan R Lambert
Department of Haematology, University College London Cancer Institute, London, UK
Blood 115:2763-8. 2010....
- Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trialAlan K Burnett
Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
J Clin Oncol 28:586-95. 2010..To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelodysplastic syndrome by comparing induction options and the number of consolidation courses and whether consolidation should include transplantation...
- Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett
Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
J Clin Oncol 29:369-77. 2011..We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients...
- Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti
Department of Haematology, Birmingham Heartlands Hospital, University College Hospital, London, UK
Br J Haematol 119:1125-32. 2002....
- Redefining transplant in acute leukemiaRob Sellar
Department of Haematology, University College London Hospital, UK
Curr Treat Options Oncol 12:312-28. 2011..The importance of enrolling patients into suitable prospective clinical trials cannot be overstated...
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsDavid Grimwade
Department of Medical and Molecular Genetics, King s College London School of Medicine and Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom
Blood 116:354-65. 2010..This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961...
- Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL TAdele K Fielding
University College London, London, United Kingdom
Blood 113:4489-96. 2009..This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223...
- Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialJonathan I Sive
Department of Haematology, University College London Hospital, London
Br J Haematol 157:463-71. 2012..New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients...
- Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioningWilliam M Townsend
Department of Haematology, University College London Hospitals NHS Foundation Trust and UCL Medical School, London, UK
Br J Haematol 161:578-86. 2013..Reduced intensity Allo-HSCT patients admitted to ICU with critical illness have improved survival compared to myeloablative Allo-HSCT recipients...
- Long-term results of the MRC AML10 trialAlan K Burnett
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
Clin Adv Hematol Oncol 4:445-51. 2006
- Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infectionKarl S Peggs
Department of Haematology, University College London, London, United Kingdom
Biol Blood Marrow Transplant 9:198-205. 2003....
- Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myelomaCharalampia Kyriakou
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 129:763-70. 2005..We conclude that the CDT regimen is safe, well tolerated and effective in patients with relapsed and refractory myeloma...
- A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentAlan K Burnett
Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
Cancer 109:1114-24. 2007..The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach...
- Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993Bella Patel
Department of Haematology, University College London Medical School, London
Br J Haematol 148:80-9. 2010..These data provide a rationale for introducing MRD-based risk stratification in future studies for the delineation of those at significant risk of treatment failure in whom intensification of therapy should be evaluated...
- Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effectsShirley D'Sa
Department of Haematology, University College London Hospitals NHS Trust, London, UK
Br J Haematol 125:756-65. 2004..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
- Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experienceJonathan Sive
Department of Haematology, University College London Hospital, London, UK
Leuk Lymphoma 53:2397-404. 2012..An ACU/hotel-based treatment model can be safely used for a wide variety of cancers and treatments, expanding hospital treatment capacity, and freeing up inpatient beds for those patients requiring them...
- Transplants in Adult ALL--? Allo for everyoneAnthony H Goldstone
Department of Haematology, University College London Hospitals, London, United Kingdom
Biol Blood Marrow Transplant 15:7-10. 2009..If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly. The MRC/ECOG study, the emerging MUD and RIC data all help establish allogeneic transplant more widely in this disease...
- Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty
Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
Blood 99:1071-8. 2002..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...
- Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour
Department of Haematology, University College London, UCL Cancer Institute, WC1E 6BT, United Kingdom
J Clin Oncol 27:4352-6. 2009..We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol...
- Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignanciesKatharine Branson
CR UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
J Clin Oncol 20:4022-31. 2002..The aim of the current study was to evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoid malignancy after failure of autologous SCT...
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialNorbert Schmitz
Department of Internal Medicine II, University of Kiel, Kiel, Germany
Lancet 359:2065-71. 2002..We aimed to compare this treatment with conventional aggressive chemotherapy without stem-cell transplantation (Dexa-BEAM)...
- The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trialAlan K Burnett
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
Br J Haematol 118:385-400. 2002..This trial found no survival advantage in children, patients over 35 years or good-risk disease...
- Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJose A Perez-Simon
Department of Hematology, Hospital Universitairo de Salamanca, Paseo de San Vicente s n, 37007 Salamanca, Spain
Blood 100:3121-7. 2002..Patients receiving alemtuzumab often required DLIs to achieve similar tumor control but the incidence of GVHD was not significantly increased after DLI...
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Jacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
Blood 106:3760-7. 2005..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor...
- Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant RegistriesElisabeth Vandenberghe
Department of Haematology, St James Hospital, Dublin, Ireland
Br J Haematol 120:793-800. 2003..99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR...
- Conventional allograft and autograft in low grade lymphomaIrit Avivi
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, P O Box 9602, Haifa 31096, Israel
Best Pract Res Clin Haematol 18:113-28. 2005..However, data is still limited and follow-up in the majority of studies is relatively short, highlighting the need for longer follow-up to establish the role of reduced intensity SCT in low grade lymphoma...
- The allogeneic effect in non-Hodgkin's lymphomaAnthony H Goldstone
North London Cancer Network, 6th Floor, Rosenheim Wing, 25 Grafton Way, London WC1E 6DB, UK
Leuk Lymphoma 44:S91-7. 2003..However, treatment will be improved by optimizating conditioning regimens and a better understanding of patient selection criteria and the immune processes involved in graft-vs.-host disease and GVT...
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris
Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
Blood 102:404-6. 2003..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
- Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemiaChristine J Harrison
Leukaemia Research Fund Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton, UK
Br J Haematol 125:552-9. 2004..Thus cytogenetics, or at least a clear definition of the modal chromosome number, is essential at diagnosis in order to stratify patients with hypodiploidy into the appropriate risk group for treatment...
- Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs
Department of Haematology, Royal Free and University College London, UK
Lancet 365:1934-41. 2005..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding
Royal Free and University College London Medical School, and Christie Hospital National Health Service Trust, Manchester, UK
Blood 109:944-50. 2007..Prevention of recurrence is the best strategy for long-term survival in this disease...
- Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman
Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, UK
Blood 109:3189-97. 2007....
- Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemiasDejan Juric
Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
J Clin Oncol 25:1341-9. 2007..To identify gene expression patterns and interaction networks related to BCR-ABL status and clinical outcome in adults with acute lymphoblastic leukemia (ALL)...
- Development of squamous cell carcinoma of the skin during induction chemotherapy for acute myeloid leukemiaPanagiotis D Kottaridis
Leuk Lymphoma 43:459-60. 2002